英文業績

Yamamoto C, Kameda H, Miyoshi H, Takase T, Fujita Y, Nomoto H, Cho KY, Nakamura A, Tatsuya Atsumi. Acromegaly cases exhibiting increased growth hormone during dipeptidyl peptidase-4 inhibitor preadministered oral glucose loading compared to oral glucose loading. Intern Med. 2021 in press

Handa T, Nakamura A, Miya A, Nomoto H, Kameda H, Cho KY, Nagai S, Yoshioka N, Miyoshi H, Atsumi T. The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: prospective observational study. Diabetol & Metabo Syndr. 13:37, 2021

Yamauchi Y, Kameda H, Nakamura A, Cho KY, Nomoto H, Omori K, Tani M, Miyoshi H, Atsumi T. Severe infection including disseminated herpes zoster triggered by subclinical Cushing’s disease: a case report. BMC endocr disord. 21:84, 2021

Sekizaki T, Kameda H, Nakamura A, Cho KY, Nomoto H, Takahasi K, Wada N, Takeuchi J, Nagai S, Miyoshi H, Atsumi T. Does dipeptidyl peptidase-4 inhibitor exacerbate Graves’ disease? J Diabetes Invest. 2021 in press

Suzuki K, Suda G, Yamamoto Y, Furuya K, Nakamura A, Miyoshi H, Ogawa K, Ohnishi S, Sakamoto N; NORTE Study Group. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 56(2):168-180, 2021

Miya A, Nakamura A, Handa T, Nomoto H, Kameda H, Cho KY, Nagai S, Ito Y, Miyoshi H, Atsumi T. Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring. Sci Rep. 11:9057, 2021

Cho KY, Nomoto H, Nakamura A, Omori K, Takase T, Miya A, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H*. Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Invest. 2020 in press

Miya A, Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Impaired insulin secretion predicting unstable glycemic variability and Time-Below-Range in type 2 diabetes regardless of HbA1c or diabetes treatment. J Diabetes Invest. 2020 in press

Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H*. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin. J Diabetes Invest. 13479, 2021

Yuno A, Kenmotsu Y, Takahashi Y, Kameda H, Miyoshi H, Atsumi T, Sawamura Y, Akira Shimatsu. Successful management of active Cushing’s disease complicated with COVID-19 pneumonia. Endocr J. 68:477-484, 2021

Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T, and the J-BRAND Registry Group. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Res Care. 9:e001787, 2021

Kimura Y, Higuchi I, Kobayashi M, Furugen A, Narumi K, Nakamura A, Miyoshi H, Atsumi T, Iseki K. The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes. Drug Metab Pharmacokinet. 37:100376, 2021

Miyoshi H*. Baxter M, Kimura T, Hattori M, Morimoto Y, Marinkovich D, Tamiwa M, Hirose T. A real-world,observational study of the initiation, use ,and effectivensee of basal-bolus or premixed insulin in Japanese people with type 2 diabetes. Diabetes Ther. 12:1341-1357, 2021

Tsuchida K, Nakamura A, Miyoshi H*.Yang K, Yamaguchi Y, Kawata S, Omori K, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Seino Y, Terauchi Y, Atsumi T. Glucokinase is required for high-induced beta-call mass espansion in mice. J Diabetes Invest. 2021 in press

Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H*. Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin: Secondary Analyses of the CALMER study. J Diabetes Invest. 2021 in press